Search results
7 ian. 2022 · The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. Article 06 March 2020. TMPRSS4, a type II transmembrane serine protease, as a potential...
- Metrics
Metrics - The proprotein convertase furin in cancer: more...
- Full Size Table
Full Size Table - The proprotein convertase furin in cancer:...
- Full Size Image
Full Size Image - The proprotein convertase furin in cancer:...
- Metrics
Acum 1 zi · The selection of appropriate second-line therapy for liver cancer after first-line treatment failure poses a significant clinical challenge due to the lack of direct comparative studies and standard treatment protocols. A network meta-analysis (NMA) provides a robust method to systematically evaluate the clinical outcomes and adverse effects of various second-line treatments for hepatocellular ...
1 iun. 2018 · Indeed, we showed that EVs from Paclitaxel treated PC1/3 KD cells could escape glioma resistance to treatment. To conclude, these experimental observations lay the basis for a cell therapy based on EVs released by PC1/3 KD macrophages activated with Paclitaxel.
1 mar. 2022 · Treatment of Breast Cancer With BRCA1 Mutation: Current Practice and Future Directions. In general, the most common treatments for BC include a combination of surgery, radiation, chemotherapy, hormone therapy, targeted therapy, and immunotherapy.
23 oct. 2019 · One of the main concerns in surgical treatment of BRCA1/BRCA2 pathogenic variant breast cancer is whether the treatment outcome of breast-conserving surgery (BCS) combined with radiotherapy is equivalent to that of radical mastectomy.
26 oct. 2022 · The study demonstrated that the Parsortix ® PC1 System can effectively capture and harvest CTCs from the peripheral blood of MBC patients and that the harvested cells can be evaluated using orthogonal methodologies such as gene expression and/or Fluorescence In Situ Hybridization (FISH).
25 ian. 2022 · To inform clinical management strategies and optimize guidelines for cancer risk management in female and male BRCA1/2 carriers, we comprehensively assess the associations of BRCA1/2 PVs with risks of 22 cancers, other than female breast and ovarian cancers.
